Davis's Drug Guide
pembrolizumab
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Genetic Implications:
Pronunciation:
pem-broe-li-zoo-mab
To hear audio pronunciation of this topic, purchase a subscription or log in.Trade Name(s)
- Keytruda
Ther. Class.
Pharm. Class.
monoclonal antibodies
programmed death-1 inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Pembrolizumab." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2024. Medicine Central, im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110182/all/pembrolizumab.
Vallerand AHA, Sanoski CAC, Quiring CC. Pembrolizumab. Davis's Drug Guide. F.A. Davis Company; 2024. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110182/all/pembrolizumab. Accessed December 24, 2024.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2024). Pembrolizumab. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110182/all/pembrolizumab
Vallerand AHA, Sanoski CAC, Quiring CC. Pembrolizumab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2024. [cited 2024 December 24]. Available from: https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110182/all/pembrolizumab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - pembrolizumab
ID - 110182
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110182/all/pembrolizumab
PB - F.A. Davis Company
ET - 19
DB - Medicine Central
DP - Unbound Medicine
ER -
